Exiris, in collaboration with the Italian Institute of Health (ISS), Rome and with Aldevron Freiburg Germany, has generated a novel antibody that shows efficacy against colon cancer stem cell and hepatocellular carcinoma xenograft models. This discovery is subject of a patent application.
Aug
16
Comments are closed.